Lausanne, 6 September 2016
The pan-European project RHAPSODY reunites researchers and experts from 26 partner Institutions, in both the public and private sectors, to improve the diagnosis of and fight against type 2 diabetes (T2D). SIB Swiss Institute of Bioinformatics is in charge of coordinating the integration of existing clinical data.
With over 420 million people suffering from diabetes worldwide, improving the process involved in the diagnosis and fight against this disease is a priority. RHAPSODY (Risk Assessment and ProgreSsion of Diabetes) is a European consortium bringing together prominent European experts – among which SIB Swiss Institute of Bioinformatics – to identify, validate and characterize causal biomarkers of type 2 diabetes, the most common form of the disease. SIB acts as the Data Coordination Center for the project, ensuring data standardization and integration of genomic, biochemical and clinical data from large patient cohorts. The project is funded by the Innovative Medicine Initiative (IMI), a public-private partnership between the European Union – represented by the European Commission – and the pharma industry and will allow major advances in precision therapy.